Boston gets US nod for Liberte stent, firm pits DES vs bypass
This article was originally published in Clinica
Executive Summary
The US FDA has given Boston Scientific the all-clear to sell its new bare metal coronary stent, Liberte, which will also serve as the platform for the firm's next-generation paclitaxel-eluting stent, Taxus Liberte. The company has also begun what it calls a groundbreaking trial to compare drug-eluting stents (DESs) with heart bypass surgery in patients with the severest form of coronary artery disease.
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.